share_log

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

在收益增长方面,3sBio(HKG: 1530)勾选了所有方框
Simply Wall St ·  2023/12/07 17:02

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

对于初学者来说,收购一家向投资者讲述好故事的公司似乎是个好主意(也是一个令人兴奋的前景),即使该公司目前缺乏收入和利润记录。不幸的是,这些高风险投资通常几乎不可能获得回报,许多投资者为吸取教训付出了代价。亏损的公司尚未用利润证明自己,最终外部资本的流入可能会枯竭。

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like 3SBio (HKG:1530). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.

尽管处于科技股蓝天投资时代,但许多投资者仍然采用更传统的策略:购买3sBio(HKG: 1530)等盈利公司的股票。尽管这并不一定说明其价值是否被低估,但该业务的盈利能力足以保证一定程度的升值,尤其是在其增长的情况下。

Check out our latest analysis for 3SBio

查看我们对 3sBio 的最新分析

How Fast Is 3SBio Growing?

3sBio 的增长速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. We can see that in the last three years 3SBio grew its EPS by 15% per year. That's a good rate of growth, if it can be sustained.

如果你认为市场的效率甚至含糊不清,那么从长远来看,你预计公司的股价将遵循其每股收益(EPS)的业绩。因此,有很多投资者喜欢购买每股收益增长的公司的股票。我们可以看到,在过去三年中,3sBio的每股收益每年增长15%。如果能够持续的话,这是一个不错的增长率。

It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. 3SBio shareholders can take confidence from the fact that EBIT margins are up from 26% to 31%, and revenue is growing. Ticking those two boxes is a good sign of growth, in our book.

查看息税前收益(EBIT)利润率以及收入增长通常会有所帮助,这样可以重新了解公司的增长质量。息税前利润率从26%上升到31%,收入在增长,3sBio股东可以从这一事实中获得信心。在我们的书中,勾选这两个方框是增长的好兆头。

The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.

下图显示了该公司的收入和收入随着时间的推移是如何发展的。要了解更多细节,请点击图片。

earnings-and-revenue-history
SEHK:1530 Earnings and Revenue History December 7th 2023
香港交易所:1530 收益和收入记录 2023 年 12 月 7 日

While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for 3SBio?

尽管我们生活在当下,但毫无疑问,未来在投资决策过程中最为重要。那么,为什么不查看这张描述3sBio未来每股收益估计值的交互式图表呢?

Are 3SBio Insiders Aligned With All Shareholders?

3sBio Insiders 是否与所有股东保持一致?

It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. 3SBio followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. We note that their impressive stake in the company is worth CN¥1.1b. This suggests that leadership will be very mindful of shareholders' interests when making decisions!

公司领导者的行为必须符合股东的最大利益,因此内幕投资始终是市场的保证。3sBio的追随者会感到欣慰的是,内部人士拥有大量资本,可以将其最大利益与更广泛的股东群体保持一致。我们注意到,他们在该公司的可观股份价值11亿元人民币。这表明,领导层在做出决策时会非常注意股东的利益!

Does 3SBio Deserve A Spot On Your Watchlist?

3sBio 值得在你的关注名单上占有一席之地吗?

As previously touched on, 3SBio is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. The combination definitely favoured by investors so consider keeping the company on a watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if 3SBio is trading on a high P/E or a low P/E, relative to its industry.

如前所述,3sBio是一家成长型企业,这令人鼓舞。对于那些寻求更多收益的人来说,高水平的内部所有权增强了我们对这种增长的热情。这种组合肯定受到投资者的青睐,因此可以考虑将公司列入观察名单。尽管我们已经研究了收益的质量,但我们还没有为股票估值做任何工作。因此,如果您想便宜地购买,则可能需要检查3sBio相对于其行业而言是高市盈率还是低市盈率。

The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.

投资的好处在于,你几乎可以投资任何你想要的公司。但是,如果你更喜欢关注表现出内幕买入的股票,以下是过去三个月内进行内幕买入的公司名单。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

请注意,本文中讨论的内幕交易是指相关司法管辖区内应报告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发